研究热点和阿尔茨海默病和肠道微生物群的边界:知识映射和文本挖掘分析
Youao Zhang1,2, Zixuan Jia3, Jieyan Wang4
1Department of Urology, People's Hospital of Longhua, No.38 Jinglong Jianshe Road, 518109, Shenzhen, China.
Molecular neurobiology
|April 17, 2024
概括
研究表明,肠道微生物群与阿尔茨海默病 (AD) 之间的联系越来越大. 这种文献计量分析揭示了关键的研究趋势和未来理解这种复杂关系的方向.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 图书统计学 图书统计学
背景情况:
- 阿尔茨海默病 (AD) 越来越多地与肠道微生物群有关.
- 在这个领域的研究已经出现了显著的增长.
研究的目的:
- 对肠道微生物群和AD的研究进行文献计量和视觉分析.
- 确定出版趋势,主要贡献者和研究热点.
主要方法:
- 从科学网络核心收藏中对1093篇出版物的图书法分析.
- 使用VOSviewer,COOC13.2,Citespace,HistCite和R-Studio进行数据分析.
主要成果:
- 观察到出版物的持续上升趋势.
- 中国在出版物方面处于领先地位,江大学是顶级机构,而Walter J Lukiw是最多产的作者.
- 关键的研究领域包括肠道微生物群在阿尔茨海默病中的代谢,阿尔茨海默病治疗和相关疾病.
结论:
- 对阿尔茨海默病和肠道微生物群的研究正在迅速扩大.
- 未来的研究可能将重点放在T细胞,NLRP3炎症体和 Porphyromonas gingivalis.
- 这种分析为未来的研究方向提供了宝贵的见解.
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183